What is the appropriate dosing frequency of Nikoran (nicorandil) 5 mg for a patient after percutaneous transluminal coronary angioplasty (PTCA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nikoran (Nicorandil) 5 mg Dosing Frequency Post-PTCA

Nikoran 5 mg should be given twice daily (BID) for a post-PTCA patient with single vessel disease.

Recommended Dosing Regimen

The standard therapeutic dosing for nicorandil in patients with coronary artery disease following PCI is 5 mg twice daily (BID), with uptitration as tolerated 1. This dosing frequency is consistently supported across multiple guidelines and clinical trials.

Evidence-Based Dosing

  • Starting dose: 5 mg BID is the recommended initial dose 1
  • Target dose: The landmark IONA trial demonstrated cardiovascular benefit with 10 mg BID initially, then 20 mg BID 2
  • Uptitration: After initiating at 5 mg BID, the dose should be increased to achieve optimal antianginal effect 1

Clinical Context for Post-PTCA Patients

Following percutaneous coronary intervention, nicorandil serves multiple therapeutic roles:

Primary indications 3, 1:

  • Add-on antianginal therapy when symptoms persist despite beta-blockers and/or calcium channel blockers
  • Treatment of microvascular spasm (particularly relevant post-PCI)
  • Cardioprotective effects during and after revascularization

Position in treatment algorithm 3:

  • The 2024 ESC guidelines position nicorandil as second-line add-on therapy (Class IIb, Level B) for inadequate symptom control
  • It may be considered as part of initial treatment in properly selected patients 3

Important Clinical Considerations

Dosing Schedule

  • Administer twice daily (morning and evening) to maintain therapeutic levels
  • The twice-daily regimen from the IONA trial showed reduction in acute coronary syndromes (HR 0.79; 95% CI, 0.64-0.98) 2

Uptitration Strategy

Starting at 5 mg BID allows assessment of tolerability before increasing to the evidence-based target of 10-20 mg BID. The 2023 AHA/ACC guidelines specifically note "nicorandil 5 mg BID, uptitrated" as the recommended approach 1.

Common Pitfalls to Avoid

  • Do not use once-daily dosing: The pharmacokinetics and clinical trial data support BID administration
  • Do not remain at 5 mg BID indefinitely: This is a starting dose; uptitration to 10-20 mg BID provides optimal cardiovascular benefit 2
  • Monitor blood pressure: Nicorandil has nitrate-like vasodilatory effects; ensure adequate blood pressure before uptitration

Safety Monitoring

  • Assess for headache (nitrate-like side effect) after initiation
  • Monitor for hypotension, particularly when combining with other vasodilators
  • Evaluate symptom control at follow-up to guide dose optimization

Evidence Quality

The BID dosing recommendation is supported by:

  • High-quality guideline evidence: 2024 ESC 3, 2023 AHA/ACC 1, and 2012 CCS/CPS guidelines 2
  • Landmark trial data: IONA trial with 5,126 patients demonstrated cardiovascular benefit with BID dosing 2
  • Consistent dosing across indications: Whether for vasospastic angina, microvascular angina, or post-PCI management, the BID frequency remains standard 1

The twice-daily frequency is essential for maintaining therapeutic drug levels and achieving the cardioprotective and antianginal effects demonstrated in clinical trials.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.